GlassScriptPhysician profile
Michele Ann Rich
NPI 1538885975
$4,688.91
in general payments reported to CMS, 2019-2025
29 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.91 · 2023: $1,268 · 2024: $1,941 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $461.50 | 2023-2025 | Lifevest |
| Pfizer INC. | $460.34 | 2023-2025 | |
| Amgen INC. | $441.31 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $411.85 | 2023-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $375.10 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $328.89 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $298.92 | 2022-2025 | Onpattro, Amvuttra |
| Abbott Laboratories | $268.81 | 2023-2025 | Cardiomems, Jot Dx, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals LP | $254.23 | 2023-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $220.17 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.91 | 2023-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $208.78 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $133.71 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $133.08 | 2023-2024 | Xarelto |
| Irhythm Technologies, INC. | $86.65 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $55.32 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Cvrx, INC. | $42.52 | 2023-2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $41.80 | 2023-2025 | Inspire |
| W. L. Gore & Associates, INC. | $35.74 | 2024 | Gore Cardioform Septal Occluder |
| Scpharmaceuticals INC. | $28.68 | 2024-2025 | |
| Boston Scientific Corporation | $25.60 | 2023 | Watchman Access System |
| Teleflex LLC | $25.05 | 2023 | Guideliner |
| Atricure, INC. | $22.75 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Esperion Therapeutics, INC. | $19.83 | 2023 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $19.46 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $19.24 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $18.06 | 2024 | Inpefa |
| Chiesi USA, INC. | $17.53 | 2024 | Kengreal |
| Vital Connect, INC | $16.08 | 2024 | Vitalpatch Rtm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.